Early changes in 2-deoxy-2-[18F]fluoro-d-glucose metabolism in squamous-cell carcinoma during chemotherapy in vivo and in vitro

Cancer Biotherapy and Radiopharmaceuticals

Volumn 24, Issue 3, 2009, Pages 327-332

  Bjurberg, Maria ^a   Henriksson, Eva ^a   Brun, Eva ^a   Ekblad, Lars ^b   Ohlsson, Tomas ^a   Brun, Arne ^a   Kjellén, Elisabeth ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

FDG PET; Metabolic flare; Phosphor imaging; Squamous cell carcinoma; Therapy monitoring; Tumor metabolism

Indexed keywords

CISPLATIN; FLUORODEOXYGLUCOSE F 18; GLUCOSE; PHOSPHORUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HYPERMETABOLISM; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR CELL; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DRUG MONITORING; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; LYMPHOCYTES; MICE; MICE, INBRED BALB C; MICE, NUDE; NECROSIS; RADIONUCLIDE IMAGING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67650803446     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2008.0556     Document Type: Article

References (21)

1. Vaupel P, Mayer A. Hypoxia in cancer: Significance and impact on clinical outcome. Cancer Metastasis Rev 2007;26:225.
2. 18F-FDG PET and PET=CT in the evaluation of cancer treatment response. J Nucl Med 2009;50:88.
3. de Geus-Oei LF, van der Heijden HFM, Corstens FHM, et al. Predictive and prognostic value of FDG-PET in non-small-cell lung cancer: A systematic review. Cancer 2007;110:1654.
4. Weber WA. Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med 2005;46:983.
5. Schwarz JK, Lin LL, Siegel BA, et al. (18)-F-fluorodeoxy-glucose-positron emission tomography evaluation of early metabolic response during radiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys 2008;72:1502.
6. Brun E, Kjellén E, Tennvall J, et al. FDG-PET studies during treatment: Prediction of therapy outcome in head and neck squamous cell carcinoma. 2002;24:127.
7. Mortimer JE, Dehdashti F, Siegel BA, et al. Metabolic flare: Indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 2001;19:2797.
8. Weber WA, Wieder H. Monitoring chemotherapy and radiotherapy of solid tumors. Eur J Nucl Med Mol Imaging 2006;33:27.
9. Henriksson E, Baldetorp B, Borg Å, et al. p53 mutation and cyclin D1 amplification correlate with cisplatin sensitivity in xenografted human squamous cell carcinomas from head and neck. Acta Oncol 2006;45:300.
10. Wennerberg J. Changes in growth pattern of human squamous-cell carcinomas of the head and neck during serial passages in nude mice. Int J Cancer 1984;33:245.
11. 18F)fluoro-D-glucose uptake and correlation to intratumoral heterogeneity. Anticancer Research 2007;27:2155.
12. 18F] fluorodeoxyglucose in human monocyte-macrophages in vitro. Eur J Nucl Med Mol Imaging 30: 267 (2003).
13. Findlay M, Young H, Cunningham D, et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: Correlation with tumor response to fluorouracil. J Clin Oncol 1996;14:700.
14. Kubota R, Yamada S, Kubota K, et al. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: High accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992;33:1972.
15. 18 FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response. Br J Cancer 2006;95:1174.
16. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006; 107:52.
17. Schelling M, Avril N, Nährig J, et al. Positron emission tomography using [(18)F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000; 18:1689.
18. Ott K, Weber WA, Lordick F, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 2006;24:4692.
19. Spaepen K, Stroobants S, Dupont P, et al. [(18)F]FDG-PET monitoring of tumour response to chemotherapy: Does [(18)F]FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging 2003;30:682.
20. Aliaga A, Rousseau JA, Cadorette J, et al. A small animal positron emission tomography study of the effect of chemotherapy and hormonal therapy on the uptake of 2-deoxy-2-[F-18]fluoro-d-glucose in murine models of breast cancer. Mol Imaging Biol 2007;9:144.
21. Basu S, Alavi A. Defining corelated parameters between "metabolic" flare and "clinical," "biochemical," and "osteo-blastic" flare and establishing guidelines for assessing response to treatment in cancer. Eur J Nucl Med Mol Imaging 2007;34:441.